FOOTPRINT-CAFÉS
21.4.2016 08:01:21 CEST | Business Wire | Press release
Footprint Cafés, a new chain of sustainable enterprise cafés that will re-invest 100% of net profits into local communities has launched today. The brainchild of Georgina Hemmingway, a graduate of the Judge Business School at the University of Cambridge, Footprint Cafés has also attracted the personal endorsement and financial support of Horizon Discovery Group plc CEO, angel investor and enterprise champion, Dr. Darrin M. Disley who was honoured in the Queen’s Birthday Honours today with a Queen’s Award for Enterprise Promotion.
Footprint Cafés aims to establish itself in every corner of the world, becoming the brand for ethically-motivated tourists, giving them an authentic local experience combined with world class standards. Over the past two year Georgina has already proved the business model works with the success of New Leaf Book café in Siem Reap, Cambodia and is now expanding the concept to the cultural city of Battambang, Cambodia. Darrin Disley, who has become a trustee of the charity, has pledged an initial $150,000 cornerstone donation to a fundraising campaign that aims to raise $1 million by 2017.
Dr. Darrin M. Disley, winner of the Queen’s Award for Enterprise Promotion, commented, “I am delighted to be supporting such a uniquely pure and socially impactful project. Georgina’s idea for Footprint Cafés originated at the Judge Business School and it is fantastic to have been part of her journey and see this come to fruition today.
“Ethical entrepreneurship is at the heart of everything I do and is also a quality which is essential for the development of any successful and sustainable growth business. I am grateful not only to be receiving recognition for the work that I have done, but also to be able support Footprint Cafés mission of addressing global illiteracy, gender inequality and local community development, one fantastic Enterprise Café at a time.”
Footprint Cafés has also launched today a second hand book donation drive. Footprint Cafés will send your donated books to Cambodia, donating any children’s books to rural schools and selling all fiction books in their cafes as holiday reads for tourists. All money raised from book sales in the cafes will be given to the local community as grants for educational projects.
Georgina Hemmingway, Founder of Footprint Cafés, added: “Tourism is one of the fastest growing sectors in the world, and it also represents a significant opportunity to connect and empower local communities. At the moment that opportunity is often wasted with profits being drained off-shore to wealthy owners. Footprint Cafes will connect the global to the local by harnessing the spending power of tourism as a force for local change and empowerment one amazing café at a time.”
-Ends-
About the book drive
Footprint Cafes needs previously loved fiction and children’s books. Individuals are encouraged to write messages inside the books to the unknown Footprint customer. Individuals who would like to donate to the drive are asked to write to Footprint cafes directly to organise collection.
Contact info@footprintcafes.org for details on how to donate your books.
About Footprint Cafés – www.footprintcafes.org
Footprint Cafés is a triple-lock social enterprise that is undertaking an audacious but achievable mission of building a chain of sustainable Enterprise Cafés that break down barriers to education and deliver impacting change to local communities.
Founded by Georgina Hemmingway the enterprise builds on the success of over the past three years New Leaf Book café in Siem Reap, Cambodia which now employs 17 staff and has generated and donated its profits to eight local organisations tackling illiteracy, gender inequality and community development
The expansion of the model into the cultural city of Battambang, Cambodia supported by the first phase of a $1 million fund-raising drive has already begun with further plans to expand through Indochina and beyond,
About Dr. Darrin M. Disley’s Queens Award
Dr. Darrin M. Disley is the co-founder and Chief Executive Officer of Horizon Discovery Group plc, a successful UK listed life science company based in Cambridge. Dr Disley has made a major contribution to raising the profile of life sciences both in Cambridge and beyond.
As part of his endeavours, he has concentrated on a voluntary programme to raise the profile of entrepreneurship and its connection with life sciences. He has given many hours of time to aid young entrepreneurs through mentoring and speaking engagements. In the past four years, over 100 young entrepreneurs have benefited from his advice, time and financial support and almost a dozen businesses have been launched, raising over ten million pounds in capital. He remains an advisor to many of them.
Darrin also provides assistance to several social enterprises, students from underprivileged backgrounds and advises and assists two universities along with Cambridge University Entrepreneurs.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160420006628/en/
Contact:
For Media Enquiries
Consilium Strategic Communications
Amber
Fennell, Jessica Hodgson, Matthew Neal
Fennell@consilium-comms.com
Tel:
+44 (0) 203 709 5700
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
